APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cyclizine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cyclizine Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchCyclizine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Cyclizine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Cyclizine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cyclizine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Cyclizine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cyclizine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cyclizine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cyclizine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cyclizine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cyclizine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cyclizine market include Teva, Glaxosmithkline, Wockhardt UK, Wabosan Arzneimittel, Pharmascript Limited, P and D Pharmaceuticals, Be-Tabs Pharmaceuticals, Aspen Pharmacare and Amoun Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cyclizine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cyclizine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cyclizine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cyclizine market size, projected growth trends, production technologies, key applications, and end-use industries.

Cyclizine Segment by Company

Teva

Glaxosmithkline

Wockhardt UK

Wabosan Arzneimittel

Pharmascript Limited

P and D Pharmaceuticals

Be-Tabs Pharmaceuticals

Aspen Pharmacare

Amoun Pharmaceutical

Amco

Aft Pharmaceuticals

Advanz Pharma

Cyclizine Segment by Type

Oral

Injection

Cyclizine Segment by Application

Migraine

Motion Sickness

Cyclizine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cyclizine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cyclizine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cyclizine significant trends, drivers, influence factors in global and regions.

6. To analyze Cyclizine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclizine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cyclizine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclizine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cyclizine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cyclizine industry.

Chapter 3: Detailed analysis of Cyclizine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cyclizine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cyclizine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cyclizine Industry Trends Table 2. Cyclizine Industry Drivers Table 3. Cyclizine Industry Opportunities and Challenges Table 4. Cyclizine Industry Restraints Table 5. Global Cyclizine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cyclizine Revenue Share by Company (2021-2026) Table 7. Global Cyclizine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Cyclizine Sales Volume Share by Company (2021-2026) Table 9. Global Cyclizine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cyclizine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cyclizine Key Company Manufacturing Base & Headquarters Table 12. Global Cyclizine Company, Product Type & Application Table 13. Global Cyclizine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cyclizine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injection Table 19. Global Cyclizine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Cyclizine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Cyclizine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Cyclizine Sales Volume Share by Type (2021-2026) Table 23. Global Cyclizine Sales Volume Share by Type (2027-2032) Table 24. Global Cyclizine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cyclizine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Cyclizine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Cyclizine Sales Value Share by Type (2021-2026) Table 28. Global Cyclizine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Migraine Table 30. Significant Companies of Motion Sickness Table 31. Global Cyclizine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Cyclizine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Cyclizine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Cyclizine Sales Volume Share by Application (2021-2026) Table 35. Global Cyclizine Sales Volume Share by Application (2027-2032) Table 36. Global Cyclizine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Cyclizine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Cyclizine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Cyclizine Sales Value Share by Application (2021-2026) Table 40. Global Cyclizine Sales Value Share by Application (2027-2032) Table 41. Global Cyclizine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Cyclizine Sales by Region (2021-2026) & (K Units) Table 43. Global Cyclizine Sales Market Share by Region (2021-2026) Table 44. Global Cyclizine Sales by Region (2027-2032) & (K Units) Table 45. Global Cyclizine Sales Market Share by Region (2027-2032) Table 46. Global Cyclizine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Cyclizine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Cyclizine Sales Value Share by Region (2021-2026) Table 49. Global Cyclizine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Cyclizine Sales Value Share by Region (2027-2032) Table 51. Global Cyclizine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Cyclizine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Cyclizine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Cyclizine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Cyclizine Sales by Country (2021-2026) & (K Units) Table 56. Global Cyclizine Sales Market Share by Country (2021-2026) Table 57. Global Cyclizine Sales by Country (2027-2032) & (K Units) Table 58. Global Cyclizine Sales Market Share by Country (2027-2032) Table 59. Global Cyclizine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Cyclizine Sales Value Market Share by Country (2021-2026) Table 61. Global Cyclizine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Cyclizine Sales Value Market Share by Country (2027-2032) Table 63. Teva Company Information Table 64. Teva Business Overview Table 65. Teva Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Teva Cyclizine Product Portfolio Table 67. Teva Recent Development Table 68. Glaxosmithkline Company Information Table 69. Glaxosmithkline Business Overview Table 70. Glaxosmithkline Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Glaxosmithkline Cyclizine Product Portfolio Table 72. Glaxosmithkline Recent Development Table 73. Wockhardt UK Company Information Table 74. Wockhardt UK Business Overview Table 75. Wockhardt UK Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Wockhardt UK Cyclizine Product Portfolio Table 77. Wockhardt UK Recent Development Table 78. Wabosan Arzneimittel Company Information Table 79. Wabosan Arzneimittel Business Overview Table 80. Wabosan Arzneimittel Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Wabosan Arzneimittel Cyclizine Product Portfolio Table 82. Wabosan Arzneimittel Recent Development Table 83. Pharmascript Limited Company Information Table 84. Pharmascript Limited Business Overview Table 85. Pharmascript Limited Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Pharmascript Limited Cyclizine Product Portfolio Table 87. Pharmascript Limited Recent Development Table 88. P and D Pharmaceuticals Company Information Table 89. P and D Pharmaceuticals Business Overview Table 90. P and D Pharmaceuticals Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. P and D Pharmaceuticals Cyclizine Product Portfolio Table 92. P and D Pharmaceuticals Recent Development Table 93. Be-Tabs Pharmaceuticals Company Information Table 94. Be-Tabs Pharmaceuticals Business Overview Table 95. Be-Tabs Pharmaceuticals Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Be-Tabs Pharmaceuticals Cyclizine Product Portfolio Table 97. Be-Tabs Pharmaceuticals Recent Development Table 98. Aspen Pharmacare Company Information Table 99. Aspen Pharmacare Business Overview Table 100. Aspen Pharmacare Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Aspen Pharmacare Cyclizine Product Portfolio Table 102. Aspen Pharmacare Recent Development Table 103. Amoun Pharmaceutical Company Information Table 104. Amoun Pharmaceutical Business Overview Table 105. Amoun Pharmaceutical Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Amoun Pharmaceutical Cyclizine Product Portfolio Table 107. Amoun Pharmaceutical Recent Development Table 108. Amco Company Information Table 109. Amco Business Overview Table 110. Amco Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Amco Cyclizine Product Portfolio Table 112. Amco Recent Development Table 113. Aft Pharmaceuticals Company Information Table 114. Aft Pharmaceuticals Business Overview Table 115. Aft Pharmaceuticals Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Aft Pharmaceuticals Cyclizine Product Portfolio Table 117. Aft Pharmaceuticals Recent Development Table 118. Advanz Pharma Company Information Table 119. Advanz Pharma Business Overview Table 120. Advanz Pharma Cyclizine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Advanz Pharma Cyclizine Product Portfolio Table 122. Advanz Pharma Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Cyclizine Distributors List Table 126. Cyclizine Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Cyclizine Product Image Figure 2. Global Cyclizine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cyclizine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cyclizine Sales (2021-2032) & (K Units) Figure 5. Global Cyclizine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cyclizine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injection Image Figure 11. Global Cyclizine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Cyclizine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Cyclizine Sales Volume Share by Type (2021-2032) Figure 14. Global Cyclizine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Cyclizine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Cyclizine Sales Value Share by Type (2021-2032) Figure 17. Migraine Image Figure 18. Motion Sickness Image Figure 19. Global Cyclizine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Cyclizine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Cyclizine Sales Volume Share by Application (2021-2032) Figure 22. Global Cyclizine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Cyclizine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Cyclizine Sales Value Share by Application (2021-2032) Figure 25. Global Cyclizine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Cyclizine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Cyclizine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Cyclizine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Cyclizine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Cyclizine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Cyclizine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Cyclizine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Cyclizine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Cyclizine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Cyclizine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Cyclizine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Cyclizine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Cyclizine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Cyclizine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Cyclizine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Cyclizine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Cyclizine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Cyclizine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Migraine
  • Motion Sickness
Companies covered
  • Teva
  • Glaxosmithkline
  • Wockhardt UK
  • Wabosan Arzneimittel
  • Pharmascript Limited
  • P and D Pharmaceuticals
  • Be-Tabs Pharmaceuticals
  • Aspen Pharmacare
  • Amoun Pharmaceutical
  • Amco
  • Aft Pharmaceuticals
  • Advanz Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cyclizine Sales Value (2021-2032)
  4. 1.2.2 Global Cyclizine Sales Volume (2021-2032)
  5. 1.2.3 Global Cyclizine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cyclizine Market Dynamics
  1. 2.1 Cyclizine Industry Trends
  2. 2.2 Cyclizine Industry Drivers
  3. 2.3 Cyclizine Industry Opportunities and Challenges
  4. 2.4 Cyclizine Industry Restraints
3 Cyclizine Market by Company
  1. 3.1 Global Cyclizine Company Revenue Ranking in 2025
  2. 3.2 Global Cyclizine Revenue by Company (2021-2026)
  3. 3.3 Global Cyclizine Sales Volume by Company (2021-2026)
  4. 3.4 Global Cyclizine Average Price by Company (2021-2026)
  5. 3.5 Global Cyclizine Company Ranking (2024-2026)
  6. 3.6 Global Cyclizine Company Manufacturing Base and Headquarters
  7. 3.7 Global Cyclizine Company Product Type and Application
  8. 3.8 Global Cyclizine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cyclizine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cyclizine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cyclizine Market by Type
  1. 4.1 Cyclizine Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Cyclizine Sales Volume by Type
  5. 4.2.1 Global Cyclizine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cyclizine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Cyclizine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Cyclizine Sales Value by Type
  9. 4.3.1 Global Cyclizine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Cyclizine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Cyclizine Sales Value Share by Type (2021-2032)
5 Cyclizine Market by Application
  1. 5.1 Cyclizine Application Introduction
  2. 5.1.1 Migraine
  3. 5.1.2 Motion Sickness
  4. 5.2 Global Cyclizine Sales Volume by Application
  5. 5.2.1 Global Cyclizine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Cyclizine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Cyclizine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Cyclizine Sales Value by Application
  9. 5.3.1 Global Cyclizine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Cyclizine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Cyclizine Sales Value Share by Application (2021-2032)
6 Cyclizine Regional Sales and Value Analysis
  1. 6.1 Global Cyclizine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cyclizine Sales by Region (2021-2032)
  3. 6.2.1 Global Cyclizine Sales by Region: 2021-2026
  4. 6.2.2 Global Cyclizine Sales by Region (2027-2032)
  5. 6.3 Global Cyclizine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cyclizine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cyclizine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cyclizine Sales Value by Region (2027-2032)
  9. 6.5 Global Cyclizine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cyclizine Sales Value (2021-2032)
  12. 6.6.2 North America Cyclizine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cyclizine Sales Value (2021-2032)
  15. 6.7.2 Europe Cyclizine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cyclizine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cyclizine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cyclizine Sales Value (2021-2032)
  21. 6.9.2 South America Cyclizine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cyclizine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cyclizine Sales Value Share by Country, 2025 VS 2032
7 Cyclizine Country-level Sales and Value Analysis
  1. 7.1 Global Cyclizine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cyclizine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cyclizine Sales by Country (2021-2032)
  4. 7.3.1 Global Cyclizine Sales by Country (2021-2026)
  5. 7.3.2 Global Cyclizine Sales by Country (2027-2032)
  6. 7.4 Global Cyclizine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cyclizine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cyclizine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cyclizine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cyclizine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cyclizine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cyclizine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cyclizine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cyclizine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cyclizine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cyclizine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cyclizine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cyclizine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cyclizine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cyclizine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cyclizine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cyclizine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cyclizine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cyclizine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cyclizine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cyclizine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cyclizine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cyclizine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cyclizine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cyclizine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cyclizine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cyclizine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cyclizine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cyclizine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cyclizine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cyclizine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cyclizine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cyclizine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cyclizine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cyclizine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cyclizine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cyclizine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cyclizine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cyclizine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cyclizine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cyclizine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cyclizine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cyclizine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cyclizine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cyclizine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cyclizine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cyclizine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cyclizine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cyclizine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cyclizine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cyclizine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cyclizine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cyclizine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cyclizine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cyclizine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cyclizine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cyclizine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cyclizine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cyclizine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cyclizine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cyclizine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cyclizine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cyclizine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cyclizine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cyclizine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cyclizine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cyclizine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cyclizine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cyclizine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cyclizine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cyclizine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cyclizine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cyclizine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cyclizine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cyclizine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cyclizine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cyclizine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cyclizine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cyclizine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cyclizine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cyclizine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cyclizine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cyclizine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cyclizine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cyclizine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cyclizine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cyclizine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Cyclizine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Cyclizine Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Glaxosmithkline
  8. 8.2.1 Glaxosmithkline Company Information
  9. 8.2.2 Glaxosmithkline Business Overview
  10. 8.2.3 Glaxosmithkline Cyclizine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Glaxosmithkline Cyclizine Product Portfolio
  12. 8.2.5 Glaxosmithkline Recent Developments
  13. 8.3 Wockhardt UK
  14. 8.3.1 Wockhardt UK Company Information
  15. 8.3.2 Wockhardt UK Business Overview
  16. 8.3.3 Wockhardt UK Cyclizine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Wockhardt UK Cyclizine Product Portfolio
  18. 8.3.5 Wockhardt UK Recent Developments
  19. 8.4 Wabosan Arzneimittel
  20. 8.4.1 Wabosan Arzneimittel Company Information
  21. 8.4.2 Wabosan Arzneimittel Business Overview
  22. 8.4.3 Wabosan Arzneimittel Cyclizine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Wabosan Arzneimittel Cyclizine Product Portfolio
  24. 8.4.5 Wabosan Arzneimittel Recent Developments
  25. 8.5 Pharmascript Limited
  26. 8.5.1 Pharmascript Limited Company Information
  27. 8.5.2 Pharmascript Limited Business Overview
  28. 8.5.3 Pharmascript Limited Cyclizine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pharmascript Limited Cyclizine Product Portfolio
  30. 8.5.5 Pharmascript Limited Recent Developments
  31. 8.6 P and D Pharmaceuticals
  32. 8.6.1 P and D Pharmaceuticals Company Information
  33. 8.6.2 P and D Pharmaceuticals Business Overview
  34. 8.6.3 P and D Pharmaceuticals Cyclizine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 P and D Pharmaceuticals Cyclizine Product Portfolio
  36. 8.6.5 P and D Pharmaceuticals Recent Developments
  37. 8.7 Be-Tabs Pharmaceuticals
  38. 8.7.1 Be-Tabs Pharmaceuticals Company Information
  39. 8.7.2 Be-Tabs Pharmaceuticals Business Overview
  40. 8.7.3 Be-Tabs Pharmaceuticals Cyclizine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Be-Tabs Pharmaceuticals Cyclizine Product Portfolio
  42. 8.7.5 Be-Tabs Pharmaceuticals Recent Developments
  43. 8.8 Aspen Pharmacare
  44. 8.8.1 Aspen Pharmacare Company Information
  45. 8.8.2 Aspen Pharmacare Business Overview
  46. 8.8.3 Aspen Pharmacare Cyclizine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Aspen Pharmacare Cyclizine Product Portfolio
  48. 8.8.5 Aspen Pharmacare Recent Developments
  49. 8.9 Amoun Pharmaceutical
  50. 8.9.1 Amoun Pharmaceutical Company Information
  51. 8.9.2 Amoun Pharmaceutical Business Overview
  52. 8.9.3 Amoun Pharmaceutical Cyclizine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Amoun Pharmaceutical Cyclizine Product Portfolio
  54. 8.9.5 Amoun Pharmaceutical Recent Developments
  55. 8.10 Amco
  56. 8.10.1 Amco Company Information
  57. 8.10.2 Amco Business Overview
  58. 8.10.3 Amco Cyclizine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Amco Cyclizine Product Portfolio
  60. 8.10.5 Amco Recent Developments
  61. 8.11 Aft Pharmaceuticals
  62. 8.11.1 Aft Pharmaceuticals Company Information
  63. 8.11.2 Aft Pharmaceuticals Business Overview
  64. 8.11.3 Aft Pharmaceuticals Cyclizine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Aft Pharmaceuticals Cyclizine Product Portfolio
  66. 8.11.5 Aft Pharmaceuticals Recent Developments
  67. 8.12 Advanz Pharma
  68. 8.12.1 Advanz Pharma Company Information
  69. 8.12.2 Advanz Pharma Business Overview
  70. 8.12.3 Advanz Pharma Cyclizine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Advanz Pharma Cyclizine Product Portfolio
  72. 8.12.5 Advanz Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cyclizine Value Chain Analysis
  2. 9.1.1 Cyclizine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cyclizine Sales Mode & Process
  6. 9.2 Cyclizine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cyclizine Distributors
  9. 9.2.3 Cyclizine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst